# A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

> **NCT02304393** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 140 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Selicrelumab

## Key facts

- **NCT ID:** NCT02304393
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-12
- **Primary completion:** 2019-11-07
- **Final completion:** 2019-11-07
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304393, "A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02304393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*